Active, not recruitingPhase 3NCT05668988
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dizal Pharmaceuticals
- Principal Investigator
- Caicun ZhouShanghai Pulmonary Hospital, Shanghai, China
- Intervention
- sunvozertinib(drug)
- Enrollment
- 324 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- OPN Healthcare, Inc., Glendale, California, United States
- Kaiser Permanente Medical Center, Vallejo, California, United States
- University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- D&H Cancer Research Center LLC, Margate, Florida, United States
- BRCR Medical Center Inc., Plantation, Florida, United States
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- NYU Laura & Issac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Gabrail Cancer Center Research, Canton, Ohio, United States
- OSU Brain & Spine Hospital, Columbus, Ohio, United States
- Providence Portland Institute Franz, Portland, Oregon, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
- The University of Texas MD Anderson cancer center, Houston, Texas, United States
- exas Oncology--McAllen, Weslaco, Texas, United States
- University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05668988 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital